Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers

Rebecca Lock(Akebia Therapeutics (United States)), Karen Cichowski(Brigham and Women's Hospital)

Journal of Clinical Investigation

May 8, 2016

10.1172/jci85183

Cited by 43

Related Papers

The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor

|Cancer Cell|2013|135

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence

|Cell Reports|2017|109

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

|Sarcoma|2019|74

AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution

|Nature|2024|56

Imaging Mass Spectrometry Reveals Tumor Metabolic Heterogeneity

|iScience|2020|32